Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Abbott Laboratories (NY:ABT)

131.37 -0.09 (-0.07%)
Official Closing Price Updated: 7:00 PM EDT, Aug 28, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Abbott Laboratories

< Previous 1 2 3 4 5 6 7 8 9
...
47 48 Next >
2 Reasons to Watch ABT and 1 to Stay Cautious
Abbott Laboratories currently trades at $131.61 per share and has shown little upside over the past six months, posting a small loss of 4.6%. The stock also fell short of the S&P 500’s 8.8% gain during... 
Via StockStory
Topics Stocks Supply Chain
Navigating the Currents: Top Sectors Primed for Growth in Q3 2025
The global economy is sailing into Q3 2025 with a blend of cautious optimism and persistent challenges. While a new tariff regime and elevated geopolitical tensions introduce elements of uncertainty,... 
Via MarketMinute
Topics Artificial Intelligence Economy Retirement
EU Rushes To Scrap Tariffs On US Goods To Unlock Lower American Auto Duties: These Exporters Stand To Gain Big
EU set to scrap tariffs on U.S. goods in a key auto trade deal. See which American industrial and energy stocks are poised for a boost. 
Via Benzinga
Topics World Trade
3 Unstoppable Dividend Stocks to Buy Right Now
Investors will get great dividends and more with these stocks. 
Via The Motley Fool
Topics World Trade
2 High-Yield Dividend Stocks to Buy in August and Hold for a Decade or Longer
These high-yield dividend stocks are built to last. 
Via The Motley Fool
Topics Intellectual Property
1 Cash-Producing Stock for Long-Term Investors and 2 We Question
While strong cash flow is a key indicator of stability, it doesn’t always translate to superior returns. Some cash-heavy businesses struggle with inefficient spending, slowing demand, or weak... 
Via StockStory
2 Stocks to Buy on the Dip and Hold for 10 Years
There should be plenty of long-term upside for these stocks for investors willing to ride out the storm. 
Via The Motley Fool
Topics Economy Government
Abbott Laboratories (NYSE:ABT): A High-Quality Dividend Stock with Strong Growth and Financial Health
Via Chartmill
Looking Into Abbott Laboratories's Recent Short Interest
 
Via Benzinga
3 Dividend Stocks to Double Up On Right Now
These stocks offer great dividends and more. 
Via The Motley Fool
Topics Economy Government World Trade
1 Healthcare Stock for Long-Term Investors and 2 We Ignore
Personal health and wellness is one of the many secular tailwinds for healthcare companies. Despite the rosy long-term prospects, short-term headwinds such as COVID inventory destocking have harmed the... 
Via StockStory
Topics Stocks
Recent Filing Shows That Rep. Josh Gottheimer Sold Over $6K Worth of Abbott Laboratories Stock
 
Via Benzinga
3 Stocks Retirees Should Absolutely Love
These stocks check off all the boxes for investors no longer receiving a paycheck. 
Via The Motley Fool
Topics Economy Retirement
Medical Devices & Supplies - Diversified Stocks Q2 Highlights: Abbott Laboratories (NYSE:ABT)
Wrapping up Q2 earnings, we look at the numbers and key takeaways for the medical devices & supplies - diversified stocks, including Abbott Laboratories (NYSE:ABT) and its peers. 
Via StockStory
The August-September Slump: Understanding Seasonal Trends in the Stock Market
As the summer months draw to a close, a familiar pattern emerges on Wall Street: the historical August-September slump. This seasonal weakness, particularly pronounced in the S&P 500, is once again... 
Via MarketMinute
Topics Economy Stocks World Trade
2 Top Stocks to Buy Now If You Want Decades of Passive Income
These companies have provided strong returns to long-term shareholders, but they aren't done yet. 
Via The Motley Fool
Topics Credit Cards
Abbott Laboratories (NYSE:ABT) Meets the Caviar Cruise Quality Investing Standards
The Caviar Cruise strategy identifies high-quality stocks like Abbott Labs (ABT) with steady growth, strong ROIC, low debt, and reliable cash flow for long-term investors. 
Via Chartmill
This New ETF Brings Out The Best In S&P 500 Without The Tech Overload
Xtrackers SPXD ETF offers a balanced way to invest in S&P 500 without relying on tech giants like Nvidia. Its innovative approach prioritizes actual economic activity and has affordable fees. 
Via Benzinga
Topics ETFs Stocks
The Smartest Dividend Stocks to Buy With $350 Right Now
These stocks offer juicy dividends, solid growth prospects, and stability. 
Via The Motley Fool
5 Dividend Stocks to Hold for the Next 20 Years
Discover five unstoppable dividend stocks that could pay you for life, and why I wouldn't sell any of them! 
Via The Motley Fool
What's going on in today's session: S&P500 movers
Stay updated with the movements of the S&P500 index one hour before the close of the markets on Friday. Discover which stocks are leading as top gainers and losers in today's session. 
Via Chartmill
Looking Into Abbott Laboratories's Recent Short Interest
 
Via Benzinga
Invesco, Vistra, Dell, Coinbase Trend In Midday Trade: S&P 500 Hits Record High
Via Stocktwits
Topics Stocks
These S&P500 stocks have an unusual volume in today's session
Let's take a closer look at the S&P500 stocks with an unusual volume in today's session on Friday. Stay informed about the market activity below. 
Via Chartmill
Top S&P500 movers in Friday's session
Let's have a look at what is happening on the US markets in the middle of the day on Friday. Below you can find the top S&P500 gainers and losers in today's session. 
Via Chartmill
Why Abbott Laboratories Is a Q2 2025 Buy: Growth & Yield
Abbott Laboratories' dividend is safe, the pipeline is strong, and the outlook for growth is positive, making the July price dip a buying opportunity. 
Via MarketBeat
These Analysts Revise Their Forecasts On Abbott Following Q2 Results
 
Via Benzinga
Microsoft To Rally More Than 14%? Here Are 10 Top Analyst Forecasts For Friday
 
Via Benzinga
ABT Q1 Deep Dive: Growth in Devices, Product Pipeline, and Tariff Mitigation Shape Outlook
Healthcare product and device company Abbott Laboratories (NYSE:ABT) beat Wall Street’s revenue expectations in Q2 CY2025, with sales up 7.4% year on year to $11.14 billion. Its non-GAAP profit of... 
Via StockStory
Topics Economy World Trade
Abbott Reports 12% Growth in Device Sales
Via The Motley Fool
< Previous 1 2 3 4 5 6 7 8 9
...
47 48 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.